Literature DB >> 12504786

Attenuated arterial and venous constriction in conscious rats with streptozotocin-induced diabetes.

Xing Cheng1, Susan W S Leung, Su L Lim, Catharine C Y Pang.   

Abstract

We examined if arterial or venous constriction is impaired in early diabetes. Dose-pressor and mean circulatory filling pressure (index of venous tone) response curves to noradrenaline and angiotensin II were constructed in four groups of conscious, instrumented, Wistar rats pretreated with streptozotocin (60 mg/kg i.v.) or vehicle at 2 weeks prior to the study. Rats with diabetes, relative to controls, had increased ED(50) (reduced potency) for the pressor (2.5-fold of control) and mean circulatory filling pressure (4.3-fold of control) response to noradrenaline, as well as reduced maximum pressor response (efficacy) to noradrenaline (diabetic, 74+/-8 mm Hg; control, 96+/-5 mm Hg). Diabetic rats also had reduced potency (ED(50), 5-fold of control) of the pressor response to angiotensin II; however, maximum pressor response and dose-mean circulatory filling pressure curve to angiotensin II were similar in both groups. Therefore, arterial and venous constrictions are impaired at an early phase of type I diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504786     DOI: 10.1016/s0014-2999(02)02762-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Involvement of RhoA/Rho kinase pathway in myogenic tone in the rabbit facial vein.

Authors:  Caroline Dubroca; Dong You; Bernard I Lévy; Laurent Loufrani; Daniel Henrion
Journal:  Hypertension       Date:  2005-04-18       Impact factor: 10.190

2.  17ß-estradiol antagonizes the down-regulation of ERα/NOS-3 signaling in vascular endothelial dysfunction of female diabetic rats.

Authors:  Yi Han; Xiaozhen Li; Suming Zhou; Guoliang Meng; Yujiao Xiao; Wen Zhang; Zhuoying Wang; Liping Xie; Zhen Liu; Hui Lu; Yong Ji
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.